Indeed, GSK343 administration led to a profound decrease in the levels of pro-inflammatory cytokines, including IL-6 and IL-1β, whereas the levels of TNF-α and IL-17A remained unaffected, indicating that GSK343 treatment reduces the inflammatory response during DSS-induced colitis (Fig. 1f). This evidence concerns the gene TNF and colitis.